Chemistry:Vixotrigine

From HandWiki
Revision as of 08:12, 8 February 2024 by WikiG (talk | contribs) (change)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Analgesic drug under development
Vixotrigine
Raxatrigine.svg
Clinical data
Other namesRaxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of
administration
By mouth
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC18H19FN2O2
Molar mass314.360 g·mol−1
3D model (JSmol)

Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[citation needed] Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker.[citation needed] As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]

See also

References

  1. "CNV1014802". Convergence Pharmaceuticals. http://www.convergencepharma.com/index.asp?page_id=14. 
  2. Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. 1 March 2013. p. 508. ISBN 978-0-7020-5374-0. https://books.google.com/books?id=ok0_jIJ0w_wC&pg=PA508. 
  3. "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–3699. August 2014. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923. 
  4. 4.0 4.1 "Vixotrigine - Biogen". Adis Insight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800027679. 

External links